EN
 
EN

Mylan Worldwide

Close

Please select one of our websites from the list below.

  1. Europe

    1. Austria
      1. Deutsch
    2. Belgium
      1. Français
      2. Nederlands
    3. Czech Republic
      1. Čeština
    4. Denmark
      1. Dansk
    5. Finland
      1. Suomi
    6. France
      1. Français
    7. Germany
      1. Deutsch
    8. Greece
      1. Ελληνικά
    9. Hungary
      1. Magyar
    10. Ireland
      1. English
    11. Italy
      1. Italiano
    12. Netherlands
      1. Nederlands
    13. Norway
      1. Norsk
    14. Poland
      1. Polski
    15. Portugal
      1. Português
    16. Slovakia
      1. Slovenský
    17. Slovenia
    18. Spain
      1. Español
    19. Sweden
      1. Svensk
    20. Switzerland
      1. Deutsch
      2. English
    21. United Kingdom
      1. English
  2. Africa

    1. South Africa
      1. English
  3. Americas

    1. Brazil
      1. Português brasileiro
    2. Canada
      1. English
      2. Français
    3. United States
      1. English
  4. Asia

    1. India
      1. English
    2. Japan
      1. 日本語
  5. Pacific

    1. Australia
      1. English
    2. New Zealand
      1. English

Mylan is also proud to do business in these locations.

  1. Morocco
  2. Luxembourg
  3. Slovenia
  1. China
  2. Singapore
  3. Taiwan
Jul 1, 2014

Therapeutic Innovation

Therapeutic Innovation

Would it surprise you to know that we bring innovation to the field of generic medicine? Or that our research and development group includes more than 2,600 scientists who innovate worldwide every day?

It’s true. And it’s why we've challenged ourselves to reach higher and go further for more than 50 years.


The Science of Solutions


Today we design bioequivalent versions of brand name medicines, many of which are difficult-to-manufacture and difficult-to-formulate. We strive to create enhanced versions of medicines to differentiate our products from the pack. And we pursue innovations in oral solid dose medicines, transdermals, injectables, creams, ointments, antiretrovirals and nearly a dozen other critical areas.

Why? Because we believe every disease can have a treatment. We believe every epidemic should come to an end. Medical conditions great and small should be manageable.

Anaphylaxis


Anaphylaxis, a life-threatening allergic reaction, is a significant public health problem. When anaphylaxis occurs, every minute matters and immediate access to adrenaline and emergency medical care is crucial. We advocate for increased anaphylaxis awareness, preparedness and access to treatment, because even one anaphylactic episode without access to adrenaline is one too many.

Antiretrovirals


These medicines treat HIV/AIDS. Often, treatment regimens require a patient to take three or more medicines and may include an ARV medicine that breaks down if not refrigerated. Many places hardest hit by the epidemic are in warm climates—Africa and India, for instance—where refrigeration can be scarce. For such regions, Mylan was able to make a heat-stable version of an ARV medicine that doesn’t require refrigeration.


Cardiovascular


Our commitment to cardiovascular medicine beats strongly. Using our transdermal technology, we have formulated adhesive patches that deliver medicine through the skin.

Respiratory


We’re developing asthma and chronic obstructive pulmonary disease (COPD) treatments that use a dry-powder drug-delivery platform technology. Find out more about our other brand name respiratory products.

Dermatology


While we manufacture products in many formats, from tablets and capsules to injectables and transdermals, we also produce creams and ointments for dermatology. Our commitment to these medicines gained strength during the 1990s, when we acquired Bertek Pharmaceuticals. Today, we have several products in clinical trials awaiting approval as well as many creams, ointments, sprays and dressings.


Central Nervous System


Mylan products are the second-most dispensed in the neurological category. These are difficult-to-manufacture and difficult-to-formulate products that treat serious diseases. Our innovation in this category has made us a leader in this area.



Last Updated:  20/03/2017